Research Analysts Set Expectations for BrainsWay Q1 Earnings

BrainsWay Ltd. (NASDAQ:BWAY - Free Report) - HC Wainwright lowered their Q1 2025 earnings per share (EPS) estimates for BrainsWay in a research report issued on Wednesday, March 12th. HC Wainwright analyst R. Selvaraju now expects that the company will earn $0.03 per share for the quarter, down from their previous forecast of $0.06. HC Wainwright currently has a "Buy" rating and a $16.00 target price on the stock. The consensus estimate for BrainsWay's current full-year earnings is $0.08 per share. HC Wainwright also issued estimates for BrainsWay's Q2 2025 earnings at $0.04 EPS, Q3 2025 earnings at $0.05 EPS, Q4 2025 earnings at $0.06 EPS, Q1 2026 earnings at $0.03 EPS, Q2 2026 earnings at $0.06 EPS, Q3 2026 earnings at $0.07 EPS, Q4 2026 earnings at $0.08 EPS and FY2026 earnings at $0.24 EPS.

BrainsWay Stock Down 0.3 %

Shares of NASDAQ BWAY traded down $0.03 during mid-day trading on Friday, hitting $10.18. 44,790 shares of the company traded hands, compared to its average volume of 75,628. BrainsWay has a 1 year low of $4.61 and a 1 year high of $11.79. The stock has a market capitalization of $191.66 million, a price-to-earnings ratio of 101.81 and a beta of 1.29. The business has a 50 day moving average of $10.27 and a two-hundred day moving average of $9.64.

Institutional Investors Weigh In On BrainsWay

Hedge funds have recently bought and sold shares of the business. JPMorgan Chase & Co. increased its position in BrainsWay by 316.3% in the 3rd quarter. JPMorgan Chase & Co. now owns 14,769 shares of the company's stock worth $136,000 after purchasing an additional 11,221 shares during the last quarter. Rhumbline Advisers increased its position in BrainsWay by 10.8% in the 4th quarter. Rhumbline Advisers now owns 21,966 shares of the company's stock worth $207,000 after purchasing an additional 2,144 shares during the last quarter. ARK Investment Management LLC acquired a new position in BrainsWay in the 4th quarter worth about $1,656,000. Sei Investments Co. acquired a new position in shares of BrainsWay during the 4th quarter valued at about $149,000. Finally, Phoenix Financial Ltd. increased its holdings in shares of BrainsWay by 100.8% during the 4th quarter. Phoenix Financial Ltd. now owns 482,724 shares of the company's stock valued at $4,552,000 after acquiring an additional 242,366 shares during the last quarter. 30.11% of the stock is owned by hedge funds and other institutional investors.

Remove Ads

BrainsWay Company Profile

BrainsWay Ltd. develops and sells noninvasive neurostimulation treatments for mental health disorders in the United States and internationally. It offers Deep Transcranial Magnetic Stimulation platform technology for the treatment of major depressive disorders, anxious depression, obsessive-compulsive disorders, smoking addiction, bipolar disorders, post traumatic stress disorders, schizophrenia, Alzheimer's disease, autism, chronic pain, multiple sclerosis, post stroke rehabilitation, and Parkinson's diseases.